Severe Cytomegalovirus Gastritis During Natalizumab-Mediated Immunosuppression

We report a 35-year-old female receiving natalizumab as monotherapy for multiple sclerosis who subsequently developed severe cytomegalovirus gastritis. As cytomegalovirus gastritis has not been previously described during natalizumab treatment, we discuss the biological plausibility of this potentia...

Descripción completa

Detalles Bibliográficos
Autores principales: Persaud, Stephen P., Hassan, Adil, Hassan, Anjum, Hassan, Tariq
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American College of Gastroenterology 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356152/
https://www.ncbi.nlm.nih.gov/pubmed/28331881
http://dx.doi.org/10.14309/crj.2017.43
_version_ 1782515760234496000
author Persaud, Stephen P.
Hassan, Adil
Hassan, Anjum
Hassan, Tariq
author_facet Persaud, Stephen P.
Hassan, Adil
Hassan, Anjum
Hassan, Tariq
author_sort Persaud, Stephen P.
collection PubMed
description We report a 35-year-old female receiving natalizumab as monotherapy for multiple sclerosis who subsequently developed severe cytomegalovirus gastritis. As cytomegalovirus gastritis has not been previously described during natalizumab treatment, we discuss the biological plausibility of this potential association and avenues for further study.
format Online
Article
Text
id pubmed-5356152
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher American College of Gastroenterology
record_format MEDLINE/PubMed
spelling pubmed-53561522017-03-22 Severe Cytomegalovirus Gastritis During Natalizumab-Mediated Immunosuppression Persaud, Stephen P. Hassan, Adil Hassan, Anjum Hassan, Tariq ACG Case Rep J Case Report We report a 35-year-old female receiving natalizumab as monotherapy for multiple sclerosis who subsequently developed severe cytomegalovirus gastritis. As cytomegalovirus gastritis has not been previously described during natalizumab treatment, we discuss the biological plausibility of this potential association and avenues for further study. American College of Gastroenterology 2017-03-15 /pmc/articles/PMC5356152/ /pubmed/28331881 http://dx.doi.org/10.14309/crj.2017.43 Text en Copyright © Persaud et al. This is an open-access article. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/
spellingShingle Case Report
Persaud, Stephen P.
Hassan, Adil
Hassan, Anjum
Hassan, Tariq
Severe Cytomegalovirus Gastritis During Natalizumab-Mediated Immunosuppression
title Severe Cytomegalovirus Gastritis During Natalizumab-Mediated Immunosuppression
title_full Severe Cytomegalovirus Gastritis During Natalizumab-Mediated Immunosuppression
title_fullStr Severe Cytomegalovirus Gastritis During Natalizumab-Mediated Immunosuppression
title_full_unstemmed Severe Cytomegalovirus Gastritis During Natalizumab-Mediated Immunosuppression
title_short Severe Cytomegalovirus Gastritis During Natalizumab-Mediated Immunosuppression
title_sort severe cytomegalovirus gastritis during natalizumab-mediated immunosuppression
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356152/
https://www.ncbi.nlm.nih.gov/pubmed/28331881
http://dx.doi.org/10.14309/crj.2017.43
work_keys_str_mv AT persaudstephenp severecytomegalovirusgastritisduringnatalizumabmediatedimmunosuppression
AT hassanadil severecytomegalovirusgastritisduringnatalizumabmediatedimmunosuppression
AT hassananjum severecytomegalovirusgastritisduringnatalizumabmediatedimmunosuppression
AT hassantariq severecytomegalovirusgastritisduringnatalizumabmediatedimmunosuppression

Ejemplares similares